Tag Archives: Acid sphingomyelinase deficiency
FDA Approves Xenpozyme: The First Disease-specific Medication for Acid Sphingomyelinase Deficiency (ASMD)
On August 31, 2022, the U.S. FDA approved Xenpozyme (Olipudase alfa) for intravenous infusion in pediatric and adult patients with […]
